Lenalidomide following whole‐brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy-Reference-Cited by-同舟云学术

Lenalidomide following whole‐brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy

Published:2023-01-22 Issue:1 Volume:201 Page:150-153
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bagal Bhausaheb¹²^ORCID,Sarma Rup¹^ORCID,Dey Sayak¹,Nayak Lingaraj¹²^ORCID,Bonda Avinash¹²,Goda Jayant¹³^ORCID,Khanna Nehal¹³,Dasgupta Archya¹³,Kakoti Sangeeta¹³,Chatarjee Abhishek¹³,Jain Hasmukh¹²^ORCID,Epari Sridhar¹⁴,Laskar Siddhartha¹³,Sengar Manju¹²^ORCID,Gupta Tejpal¹³^ORCID

Affiliation:

1. Medical Oncology Tata Memorial Centre Mumbai India

2. Homi Bhabha National Institute Mumbai India

3. Radiation Oncology Tata Memorial Centre Mumbai India

4. Pathology Tata Memorial Centre Mumbai India

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18659

Reference12 articles.

1. Management and outcome of primary CNS lymphoma in the modern era

2. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network

3. Phase II of Single-Agent Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL)

4. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Tu Resection on Survival and Functional Outcomes for Patients with Primary Central Nervous System Lymphoma;Clinical Neurology and Neurosurgery;2024-09

2. Antineoplastics;Reactions Weekly;2023-11-18